Suchergebnisse - "Özgüroğlu, Mustafa"

PubPharm (182)

71

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

enthalten in: The New England journal of medicine | 2020

von Herbst, R. | Giaccone, G. | de Marinis, F. | +19

CommentIn: N Engl J Med. 2021 Feb 11;384(6):583-584. - PMID 33567200

72

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130) : a multicentre, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2020

von Galsky, M. | Arija, J. | Bamias, A. | +24

CommentIn: Lancet. 2020 May 16;395(10236):1522-1523. - PMID 32416773

73

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy : Post Hoc Analysis of Phase 3 LATITUDE Study

enthalten in: European urology | 2020

von Matsubara, N. | Chi, K. | Özgüroğlu, M. | +11

CommentIn: Eur Urol. 2020 Aug;78(2):e89-e90. - PMID 32291107

74

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Gray, J. | Villegas, A. | Daniel, D. | +17

75

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC) : a randomised, controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2019

von Hui, R. | Özgüroğlu, M. | Villegas, A. | +15

CommentIn: Lancet Oncol. 2019 Dec;20(12):1619-1620. - PMID 31601495

76

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Paz-Ares, L. | Dvorkin, M. | Chen, Y. | +122

CommentIn: Lancet. 2019 Nov 23;394(10212):1884-1885. - PMID 31590987

77

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN) : a randomised, placebo-controlled, phase 3 study

enthalten in: The Lancet. Oncology | 2019

von Agarwal, N. | McQuarrie, K. | Bjartell, A. | +18

CommentIn: Lancet Oncol. 2019 Nov;20(11):1469-1471. - PMID 31578172

78

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

enthalten in: The New England journal of medicine | 2019

von Chi, K. | Agarwal, N. | Bjartell, A. | +118

CommentIn: N Engl J Med. 2019 Jul 4;381(1):84-86. - PMID 31269371

79

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE) : final overall survival analysis of a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Fizazi, K. | Tran, N. | Fein, L. | +12

CommentIn: Lancet Oncol. 2019 May;20(5):609-611. - PMID 30987940

80

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung : The LUX-Lung IO/KEYNOTE 497 Study Protocol

enthalten in: Clinical lung cancer | 2019

von Levy, B. | Paz-Ares, L. | Bennouna, J. | +17